You are here

Name change, new ambitions for Biogen

Company has eye on drugs for Alzheimer's, ALS; CEO to drive drug development for some hardest-to-treat diseases

Biogen is also planning a bigger move into the fledgling field of biosimilars, manufacturing cheaper versions of older biotech drugs as they lose patent protection.

New York

BIOGEN IDEC Inc has seen its market value quadruple in three years to more than US$100 billion on the back of its successful multiple sclerosis drugs. Now it has new ambitions in its sights.

The Massachusetts-based company, which made headlines last week when it announced

Market voices on:

Powered by GET.comGetCom